Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript
Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data Transcript Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants Samuel Slutsky - LifeSci Capital, LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Samantha Lynn Semenkow - Citigroup Inc. Exchange Research David Risinger - Leerink Partners LLC, Research Division Yaron Werber - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Douglas Tsao - H.C.
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevant. All of these Vants are progressing well in 2025. However, its main near-term catalyst is Brepocitinib's Phase 3 in dermatomyositis. This could become the first approved therapy for this condition.
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
